🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Cliff Asness’s SPRY Holdings & Trades

First Buy
Q1 2022
Duration Held
9 Quarters
Largest Add
Q3 2026
+61,737 Shares
Current Position
97,413 Shares
$419,851 Value

Cliff Asness's SPRY Position Overview

Cliff Asness (via Aqr Capital Management LLC) currently holds 97,413 shares of ARS Pharmaceuticals, Inc. (SPRY) worth $419,851, representing 0.00% of the portfolio. First purchased in 2022-Q1, this medium-term investment has been held for 9 quarters.

Based on 13F filings, Cliff Asness has maintained a strategic position in SPRY, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2026, adding 61,737 shares. Largest reduction occurred in Q3 2022, reducing 19,845 shares.

Analysis based on 13F filings available since 2013 Q2

Cliff Asness's ARS Pharmaceuticals (SPRY) Holding Value Over Time

Track share changes against reported price movement

Quarterly ARS Pharmaceuticals (SPRY) Trades by Cliff Asness

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 +61,737 Add 173.05% 97,413 $4.31
Q2 2026 +9,799 Add 37.87% 35,676 $8.01
Q1 2026 +25,877 New Buy 25,877 $8.03
Q3 2025 -16,132 Sold Out 0 $0.00
Q2 2025 +5,016 Add 45.12% 16,132 $17.45
Q1 2025 +11,116 New Buy 11,116 $12.58
Q3 2022 -19,845 Sold Out 0 $0.00
Q2 2022 +8,896 Add 81.25% 19,845 $4.23
Q1 2022 +10,949 New Buy 10,949 $3.47

Cliff Asness's ARS Pharmaceuticals Investment FAQs

Cliff Asness first purchased ARS Pharmaceuticals, Inc. (SPRY) in Q1 2022, acquiring 10,949 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Cliff Asness has held ARS Pharmaceuticals, Inc. (SPRY) for 9 quarters since Q1 2022.

Cliff Asness's largest addition to ARS Pharmaceuticals, Inc. (SPRY) was in Q3 2026, adding 97,413 shares worth $419,851.

According to the latest 13F filing for Q3 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 97,413 shares of ARS Pharmaceuticals, Inc. (SPRY), valued at approximately $419,851.

As of the Q3 2026 filing, ARS Pharmaceuticals, Inc. (SPRY) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.

Cliff Asness's peak holding in ARS Pharmaceuticals, Inc. (SPRY) was 97,413 shares, as reported at the end of Q3 2026.